CMS Unveils Model to Expand Coverage of Certain Weight Loss Drugs

The health agency has introduced a voluntary initiative allowing Medicare Part D and state Medicaid to cover obesity treatments.
CMS Unveils Model to Expand Coverage of Certain Weight Loss Drugs
A box of Ozempic made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams/Reuters
|Updated:
0:00

The Centers for Medicare & Medicaid Services (CMS) on Monday unveiled a voluntary model designed to expand access to GLP-1 medications for weight management and metabolic health, allowing Medicare Part D plans and state Medicaid agencies to cover these drugs while negotiating lower prices to manage expenses.

The Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) Model aims to combine GLP-1 drugs with evidence-based lifestyle interventions to improve long-term outcomes, following recent federal efforts to address affordability barriers to treatments like Ozempic and Wegovy.
Kimberly Hayek
Kimberly Hayek
Author
Kimberly Hayek is a reporter for The Epoch Times. She covers California news and has worked as an editor and on scene at the U.S.-Mexico border during the 2018 migrant caravan crisis.